MedTrace Logo

Post-Approval Study of MelaFind

NCT01700114 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 487

Last updated 2016-03-11

No results posted yet for this study

Summary

The purpose of this study is to collect data to describe the real-world use and safety and effectiveness of MelaFind® in a post-approval clinical setting.

Conditions

Interventions

DEVICE

MelaFind

The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.

Sponsors & Collaborators

  • MELA Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Armand Cognetta, MD · Dermatology Associates of Tallahassee

  • Timothy Wang, MD · The John's Hopkins University

  • Meg Gerstenblith, MD · University Hospitals Cleveland Medical Center

  • Robert Nossa, MD · The Dermatology Group, P.C

  • Arthur Sober, MD · Massachusetts General Hospital

  • Joel Cohen, MD · AboutSkin Dermatology and DermSurgery

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700114 on ClinicalTrials.gov